AllDocs -> cancers

Nitrate intake does not influence bladder cancer risk: the Netherlands Cohort Study Maurice P. Zeegers, Roel F. M. Selen, Jos C. S. Kleinjans, R. Alexandra Goldbohm, and Piet A. van den Brandt doi:10.1289/ehp.9098 (available at http://dx.doi.org/) Online 13 July 2006 The National Institute of Environmental Health Sciences National Institutes of Health U.S. Department of Health and Human Services ehp online.org Page 2 Manuscript title Nitrate intake does not influence bladder cancer risk: the Netherlands Cohort Study. Authors Maurice P. Zeegers 1,2,3 , Roel F.M Selen 3 ,Jos C.S. Kleinjans 4 , R. Alexandra Goldbohm 5 , Piet A. van den Brandt 3 . 1. Department of Public Health and Epidemiology, University of Birmingham, United Kingdom. ...

Chapter 9: Bladder cancer 91 Bladder cancer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

Andreas Böhle is Professor of Urology, Urologist and Urological Surgeon at the Helios Agnes Karll Hospital in Bad Schwartau, as well as in a in private practice. He is Chaiman of the Section of Experimental Urology of the German Society of Urology, a full member of the Commission of Guidelines of the European Association of Urology (EAU), a board member of the Clinical- Experimental Research Institution, Luebeck, among others. His main clinical and scientific interests are operative techniques in urologic oncology, endourological techniques in paediatric urology, reconstructive surgery, continent urinary derivations, photodynamic therapy, management of clinical trials, quality of life in urologic oncology, basic immunological research in tumour therapy and applied cellular, molecular and genetical tumour therapy. Professor Böhle has published numerous ...

Bladder Cancer E U R O P E A N O N C O L O G I C A L D I S E A S E 2 0 0 6 73 Arnulf Stenzl is Professor and Chairman at the Department of Urology, Eberhard-Karls-University, Tübingen, Germany. He is a member of numerous societies and organisations, including the European Society of Urologic Oncology and Endocrinology (ESUOE), the American Association of Cancer Research (AACR) and the European Association of Urology (EAU). He is the recipient of numerous awards, including an honourary ‘Professor of Urology’ title awarded by the Federal President of Austria in September 1997. Dr Stenzl is a section editor for European Urology , a guest editor for World Journal of Urology, “Urinary Diversion in the New Millennium” and Member of the Executive Board for the British Journal of Urology International . a report by ...

a report by Armin Pycha and Christine Mian Chief, Department of Urology and Biologist, Department of Pathology, General Hospital of Bolzano, Italy Superficial bladder cancer is defined as a disease that is confined to the mucosa and submucosal layers of the bladder (tumour, node, metastases (TNM) classification). As pTa and pT1 tumours can be removed by TUR, they are grouped under the heading ‘superficial bladder cancer ’ for therapeutic purposes. However, this is not a homogeneous entity, as it unites high grade lesions with low grade lesions and because the morphological presentation can be papillary or flat at the different stages of tumour – pTa, pT1 and carcinoma in situ (CIS). Furthermore, their oncogenesis runs along different pathways with different oncological potential, and therefore with varying clinical outcome. Cytogenetic ...

Proton Beam Therapy for Invasive Bladder Cancer : A Prospective Study of Bladder -Preserving Therapy with Combined Radiation Therapy and Intra-Arterial Chemotherapy I Masaharu Hata, M.D., *† Naoto Miyanaga, M.D., ‡ Koichi Tokuuye, M.D., *† Yukihisa Saida, M.D., § Kiyoshi Ohara, M.D., † Shinji Sugahara, M.D., † Kenji Kagei, M.D., *† Hiroshi Igaki, M.D., *† Takayuki Hashimoto, M.D., *† Kazunori Hattori, M.D., ‡ Toru Shimazui, M.D., ‡ Hideyuki Akaza, M.D., ‡ and Yasuyuki Akine, M.D. *† * Proton Medical Research Center, and Departments of † Radiation Oncology, ‡ Urology, and § Radiology, University of Tsukuba, Tsukuba, Ibaraki, ...

Patient Description The patient is a 79-year-old male who presents with significant urinary frequency, urgency, and moderate dysuria of about six months’ duration. He had previously received a two-week course of a fluoroquinolone antibiotic from his primary care physician without clear improvement. He denies fever, chills, flank pain, or gross hematuria. He admits to a moderate decrease in his urinary force of stream, which has remained unchanged over the past year. His medical history is remarkable for two prior diagnoses of myocardial infarction, hypertension, chronic obstructive pulmonary disease, osteoarthritis, and a cerebral vascular accident with minimal motor deficit and mild memory loss. He was treated for tuberculosis 20 years ago. He has no current angina. Medications include atenolol, hydrochlorothiazide, and low-dose ...

126 INCIDENCE In men it is the fourth most common cancer after prostate, lungs, colorectal malignancy accounting for 6.2% of all cancer cases. In women it is the eighth most common cancer accounting for 2.5% of all cancer cases. Bladder cancer is the second most common urological malignancy after prostate cancer in males. RACE Bladder cancer is roughly two times as common among American white men as among American black men and is only roughly 1.5 times more common among white American than black American women. RATIO The male to female ratio is 3:1. AGE Bladder cancer can occur at any age even in children. It usually occurs in the 4th to 5th decade of life but in the last one decade we often see this malignancy occurring in younger age group also - thanks to rapid industrialization. Younger patients appear to have more favourable ...

BLADDER CANCER - All Sections BLADDER CANCER What Is Cancer ? Cancer develops when cells in a part of the body begin to grow out of control. Although there are many kinds of cancer , they all start because of out-of-control growth of abnormal cells. Normal body cells grow, divide, and die in an orderly fashion. During the early years of a person's life, normal cells divide more rapidly until the person becomes an adult. After that, cells in most parts of the body divide only to replace worn-out or dying cells and to repair injuries. Because cancer cells continue to grow and divide, they are different from normal cells. Instead of dying, they outlive normal cells and continue to form new abnormal cells. Cancer cells often travel to other parts of the body where they begin to grow and replace normal tissue. This process, called metastasis, occurs as the cancer cells get into the bloodstream ...

Bladder Cancer a report by Alan M Nieder , MD and Mark S Soloway , MD Assistant Professor and Professor and Chairman Department of Urology, University of Miami Miller School of Medicine In 2006, over 60,000 Americans will be diagnosed with bladder cancer and over 12,000 patients will die from the disease. For patients who present with de novo muscle- invasive bladder cancer , the standard treatment is radical cystectomy, pelvic lymph node dissection and urinary diversion or pelvic radiation combined with chemotherapy. The morbidity and mortality associated with this advanced disease is not insignificant, since the five-year overall survival approaches 50%. While most patients (75%) initially present with non-muscle invasive bladder cancer , the morbidity and costs associated with this lower stage disease are also very high.These ...

Bladder Cancer a report by Matthew E Nielsen , MD , and Rober t H Getzenberg , PhD Brady Urological Institute at Johns Hopkins University School of Medicine Bladder cancer is the seventh most common cancer worldwide, with an estimated 260,000 new cases in men and 76,000 cases in women reported in 2000.The highest incidence rates of bladder cancer in both sexes have been observed in Europe, North America, and Australia.The American Cancer Society (ACS) estimated that over 60,000 new cases were diagnosed in the US in 2005,with over 15,000 deaths due to bladder cancer . In Europe, annual mortality rates from bladder cancer have been relatively stable at approximately 49,500 per year. Urothelial carcinoma arises from the transitional epithelial lining of the urinary tract. Tumors are most typically ...

Bladder Cancer a report by Rupesh Raina , MD 1 , 2 , Ashok Agarwal , PhD 1,2 , and Craig D Zippe , MD 1,2 1 Glickman Urological Institute, 2 Andrology-Oncology Research Laboratory, Cleveland Clinic Foundation, Cleveland, Ohio. The early detection of bladder cancer allows for effective local treatment and optimizes the success of surgical therapy. Survival rates reflect the importance of early diagnosis.When detected at the superficial clinical stage Ta and T1, the five-year survival rate of bladder cancer ranges between 82% and 95%, whereas corresponding survival rates for invasive muscle disease and metastatic disease are 50% and 6%, respectively. 1,2 Currently, no standard method exists for non-invasive early identification of bladder cancer . Patients who ...

Cancer in Northern Ireland 1993 - 2001: A Comprehensive Report 109 19: Cancer of the Bladder (C67) Incidence In 2001, bladder cancer was the seventh most common cancer in males and the fifteenth commonest in females. On average, 146 males and 62 females were diagnosed as having bladder cancer each year, i.e. approximately 3% and 1% respectively of all cancers registered. Age Given the level of disease in 2001, the risk of getting bladder cancer before the age of 75 years was 1 in 92 for males and 1 in 286 for females (Table 19a). Fifty percent of males were diagnosed under the age of 71 years, whilst for females it was 74 years. The average annual incidence of bladder cancer peaked at 70-74 years for both males and females, with the age-specific rates in males consistently higher than females (Figure 19a). Prevalence In Northern Ireland on 31st December 2001, there ...

Survival of Cancer Patients in Northern Ireland 1993-96 53 Incidence and Mortality In 1996, cancer of the bladder was the fifth most common cancer in men and the twelfth most common cancer in women, accounting for over 4% and 2% of all cancers registered respectively. Between 1993 and 1996, an average of 157 men and 70 women were registered each year as having bladder cancer , with the incidence of bladder cancer in women rising in this period. Women had a statistically significant upward trend (P<0.05) in their incidence EASR, corresponding to an increase of 1.2 cases per 100,000 per year. There was no statistically significant (P>0.05) trend in the incidence EASR for men (Figure 12.1). Between 1993 and 1996, approximately 63 men and 30 women died annually from bladder cancer . There were no statistically significant (P>0.05) trends in the mortality EASRs for men or women (Figure 12.1). ...

Brochure More information from http://www.researchandmarkets.com/reports/6023/ Drugs in Development for Bladder Cancer Description: This Database Table is a one-page table of hard-to-find numerical information. Database Tables are proprietary data sources covering specific information for the diagnostic, medical device, biotechnology, healthcare and IT sectors. Over 600 database tables are now available from Research and Markets. A Note on Database Tables at Research and Markets: Please note that these database tables are very focused one or two page tables/charts. They are great as a quick snapshot of a given market, or to incorporate into your own presentations/forecasts. But they not give the detailed analysis and the comprehensive information found in the full industry/market reports. If you do require more detailed market research please visit the following categories at Research and Markets: ...

23 2 © 2 006 B J U I N TER N A TI ON AL | 97, 232 –23 7 | doi:10.1111/j.1464-410X.2006.05901.x Mini-rev Article LYMPHADENECTOMY FOR BLADDER CANCER STEIN et al. Lymphadenectomy for invasive bladder cancer . II. technical aspects and prognostic factors JOHN P. STEIN, MARCUS L. QUEK and DONALD G. SKINNER From the Department of Urology, University of Southern California Keck School of Medicine, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA Accepted for publication 19 August 2005 SURGICAL BOUNDARIES OF THE LYMPHADENECTOMY An ‘extended’ lymphadenectomy must include all lymph nodes in the boundaries of: the aortic bifurcation and common iliac vessels (proximally); the genitofemoral nerve (laterally); the circumflex iliac vein and lymph node of Cloquet (distally); the hypogastric vessels (posteriorly), ...

© 20 06 B JU I N TER N A TI O N A L | 9 7, 2 27 –2 3 1 | doi:10.1111/j.1464-410X.2006.05896.x 22 7 LYMPHADENECTOMY FOR BLADDER CANCER STEIN et al. Lymphadenectomy for invasive bladder cancer : I. historical perspective and contemporary rationale JOHN P. STEIN, MARCUS L. QUEK and DONALD G. SKINNER Department of Urology, University of Southern California Keck School of Medicine, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA Accepted for publication 19 August 2005 KEYWORDS bladder cancer , cystectomy, lymphadenectomy, lymph-node metastases INTRODUCTION In the USA bladder cancer is the fourth most common cancer in men and the eighth most common in women, with TCC comprising nearly 90% of all primary bladder tumours. In 2004, it was estimated that 60 250 new ...

© 20 05 B JU I N TER N A TI O N A L | 9 5, 7 39 –7 42 | doi:10.1111/j.1464-410X.2005.05393.x 739 Blackwell Science, LtdOxford, UKBJUBJU International1464-410XBJU InternationalApril 2004 956 review Article MOLECULAR MARKERS IN BLADDER CANCER BUSCARINI et al. Molecular prognostic factors in bladder cancer MAURIZIO BUSCARINI, MARCUS L. QUEK, PARKASH GILL*, GUANGBIN XIA*, DAVID I. QUINN* and JOHN P. STEIN Departments of Urology and *Medical Oncology, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, California, USA Accepted for publication 11 October 2004 Mutations in the H-ras gene have been implicated in the development and progression of human bladder cancer . Alterations involving codons 12 and 61 of the ras oncogene have been found in up to 39% of ...

Nutrition for Bladder Cancer Dena M. Reagan, M.S., R.D., L.D. Dena M. Reagan, M.S., R.D., L.D. Clinical Dietitian Clinical Dietitian Page 2 Bladder Cancer Risk Reduction Living Well with Bladder Cancer Nutrition for Post Treatment/Survivorship Resources Page 3 Reducing Risk of Bladder Cancer with Nutrition Page 4 What may decrease risk? Liberal fluid intake Fruits/vegetables, especially cruciferous veggies Dietary selenium Sources: Brazil nuts, mixed nuts, fish Uncertain whether supplementation is beneficial Page 5 What may decrease risk? (cont’d) Dietary Supplements Vitamins E, C, A, B6, Zinc Multiple Vitamin Garlic Lactobacillus casei ...

1 Pan Birmingham Cancer Network Intravesical Therapy for the Treatment of a Bladder Tumour Patient Information Page 2 2 Introduction Your Consultant has prescribed intravesical chemotherapy for the treatment of your bladder tumour. This booklet has been written to help you understand this. It is not meant to replace discussion between you and your Consultant, but as a guide to be used together with what is discussed. If you have any questions or concerns, please do not hesitate to contact your Clinical Nurse Specialist. What is intravesical therapy? Intravesical means ‘inside the bladder ’. Intravesical therapy is a chemotherapy agent prepared in pharmacy. The name of the chemotherapy drug you will be offered will be either: Mitomycin, Epirubicin or Doxyrubicin. These drugs all work in a similar way and have similar side effects. ...

1 Pan Birmingham Cancer Network Transurethral Resection of Bladder Tumour (T.U.R.B.T) Patient Information Page 2 2 Introduction This booklet has been written to help you understand the surgery you are about to undergo. It is not meant to replace discussion between you and your Surgeon, but as a guide to be used together with what is discussed. If you have any questions or concerns, please do not hesitate to contact your Clinical Nurse Specialist. What is a bladder tumour? Your recent investigations have shown that there is a tumour inside your bladder which we suspect may be a type of cancer . There are 2 main types of bladder cancer : • Superficial bladder tumours - These tumours are confined to the inner lining of the bladder • Muscle invasive tumours - These tumours have spread to the ...

© Kamla-Raj 2004 Int J Hum Genet, 4(3): 201-205 (2004) NAT2 Gene Polymorphism in Bladder Cancer : A Study from North India D.S.L. Srivastava, A. Kumar, B. Mittal* and R.D. Mittal** *Department of Urology and Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow 226 014, Uttar Pradesh, India KEYWORDS N-acetyltransferase-2; bladder cancer ; tobacco-users; PCR-RFLP; genetic polymorphism ABSTRACT The relationship between smoking and bladder cancer risk and whether such effect is modified by the variation in NAT2 genotypes is investigated. This case control study was undertaken over a period of 19 months and included 106 bladder cancer patients and 110 controls. The NAT2 genotypes were identified by PCR-RFLP method in peripheral blood DNA samples. Genotype frequencies and the association of the genotypes among patients and controls group were assessed ...

Page 2 Mortality trends in England; ICD9 (188), ICD10 (C67); File: Sepho 96-04 V2 Bladder cancer in England 1996 to 2004. Mortality trends Authors: Michael Goldacre, Marie Duncan, Paula Cook-Mozaffari, Matthew Davidson, Henry McGuiness, Daniel Meddings Published by: Unit of Health-Care Epidemiology, Oxford University, and South-East England Public Health Observatory, 2006 This document provides a profile of trends in mortality for bladder cancer in England. The period covered is January 1 1996 to December 31 2004. The data are analysed from mortality files supplied to the South East England Public Health Observatories (SEPHO) by the Office for National Statistics (ONS). Mortality rates were calculated for the condition certified as the underlying cause of death and for the disease certified as any mention on the death certificates. Age-specific ...

Research Articles Public Health Reports / January–February 2005 / Volume 120 31 Personal Use of Hair Dyes and the Risk of Bladder Cancer : Results of a Meta-Analysis Michael Huncharek MD, MPH a Bruce Kupelnick, BA b a Division of Radiation Oncology, Department of Clinical Oncology, Marshfield Clinic Cancer Center, Marshfield, WI; Meta-Analysis Research Group, Stevens Point, WI b Meta-Analysis Research Group, Stevens Point, WI Address correspondence to: Michael Huncharek MD, MPH, Meta-Analysis Research Group, 2740 Sunset Blvd., Stevens Point, WI 54481; tel. 715-343-3035; fax 715-343-3080; e-mail <Huncharek.Michael@Marshfieldclinic.org>. ©2005 Association of Schools of Public Health SYNOPSIS Objective. This study examined the methodology of observational studies that explored an association between personal use of ...

For research use only A215- Urinary bladder cancer tissues (formalin fixed) Specifications: • No. of cases: 45 • Tissue type: Urinary bladder cancer tissues • No. of spots: 2 spots from each cancer case (90 spots) 4 non-neoplastic spots (4 spots) •Total spots: 94 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: 1 2 3 4 5 6 7 8 9 10 11 A B C D E F G H I : Urothelial carcinoma : Urothelial carcinoma in situ : Adenocarcinoma + other pathology : Squamous carcinoma : Non-neoplastic Page 2 ...

ReviewöBladder Cancer Neoadjuvant Chemotherapy in Invasive Bladder Cancer : Update of a Systematic Review and Meta-Analysis of Individual Patient Data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Meta-analysis Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK Accepted 6 April 2005 Available online 21 April 2005 Abstract Objectives: To update a systematic review and meta-analysis that assesses the effect of neoadjuvant chemotherapy in the treatment of patients with invasive bladder cancer . Methods: Following a prespecified protocol, we analysed updated individual patient data from all eligible randomised controlled trials that compared neoadjuvant chemotherapy plus local treatment with the same local treatment alone. Results: Updated results are based on 11 trials, 3005 patients; comprising 98% of all ...

ReviewöBladder Cancer Adjuvant Chemotherapy in Invasive Bladder Cancer : ASystematic Review and Meta-Analysis of Individual Patient Data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Meta-analysis Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK Accepted 6 April 2005 Available online 25 April 2005 Abstract Objectives: To evaluate the effect of adjuvant chemotherapy in invasive bladder cancer . Methods: We conducted a systematic review and meta-analysis of updated individual patient data from all available randomised controlled trials comparing local treatment plus adjuvant chemotherapy versus the same local treatment alone. Results: Analyses were based on 491 patients from six trials, representing 90% of all patients randomised in cisplatin-based combination chemotherapy trials and 66% of patients from all ...

Bladder Cancer (Transitional Cell Ca) Page 1 of 10 INITIAL SCREEN STAGING INITIAL DIAGNOSIS TUR EUA Intravesical peri- operatuve chemo- therapy (1 dose) See Page 2 CLINICAL PRESENTATION Hematuria Recurrent unex- plained urinary tract infection History and Physical Office cystoscopy* IVP Consider CT urogram Positive for Bladder Cancer Negative for Bladder Cancer See Page 5 Note: Clinical trials are considered preferred treatment options for eligible patients. This practice guideline is not intended to replace the independent medical judgment of the physician in the context of individual clinical circumstances to determine patient's care. Treat as indicated T 2-4 (Muscle Invasion) See Page 3 Less than T2 Positive for Upper ...

Chromosomal Instability in Bladder and Colon Cancer Studies involving microsatellites By Mariann Christensen, PhD, Medical Science This thesis is based on four papers in English on chromosomal instability in bladder and colon cancer . The aim has been to characterize microsatellite alter- ations in tumors and urine from patients with transitional cell carcinoma (TCC), in urinary sediments from patients with benign prostatic hyperplasia (BPH) with and without cystitis, patients belonging to families with hereditary non-polyposis colon cancer (HNPCC), and patients suspected of belonging to HNPCC families. Various molecular biological methods were applied. It is well known that germline mutations in the DNA mismatch repair genes MSH2, MLH1, PMS1, PMS2 and others are associated with HNPCC. These mu- tations give rise to microsatellite instability, which gives rise to further muta- tions ...